

## An Efficient Synthesis of $\gamma$ -Lactones as Precursors of Hydroxyethylene Dipeptide Isostere

Mitsuya Sakurai,<sup>\*a</sup> Fujio Saito,<sup>b</sup> Yasuo Ohata,<sup>b</sup> Yuichiro Yabe<sup>a</sup> and Takahide Nishi<sup>\*b</sup>

<sup>a</sup> New Lead Research and <sup>b</sup> Medicinal Chemistry Research Laboratories, Sankyo Co., Ltd., Hiromachi, Shinagawa-ku, Tokyo 140, Japan


An efficient and stereocontrolled synthesis of  $\gamma$ -lactones as precursors of the hydroxyethylene dipeptide isostere has been developed, starting from readily available 5-oxotetrahydrofuran-2-carboxylic acid **6**.

Hydroxyethylene dipeptide isostere **3** is an attractive synthetic target in the field of medicinal chemistry.<sup>1</sup> This unit is chemically stable and mimics the tetrahedral intermediate **2** formed during hydrolysis of the peptide **1** by an aspartic proteinase. Thus, compounds which incorporate this unit at the cleavage site demonstrate strong inhibition against aspartic proteinases such as renin and human immunodeficiency virus type-1 (HIV-1) protease.<sup>2</sup>

Herein we report an efficient and stereocontrolled synthesis of  $\gamma$ -lactones **4** and **5**, which can be readily converted into the hydroxyethylene dipeptide unit **3**, the most potent configuration for inhibiting renin and HIV-1 protease. Stereoselective alkylation of  $\gamma$ -lactone **5** at C-2 from the opposite side to that of the substituent at C-4 affords  $\gamma$ -lactone **4**.<sup>1c,e</sup> Our synthesis of  $\gamma$ -lactone **5** employed (*S*)-(+)-5-oxotetrahydrofuran-2-carboxylic acid **6**, which is available from the cheap L-glutamic acid,<sup>3</sup> as a starting material (Scheme 1).

The first stage of our synthesis was to obtain *syn*-hydroxy  $\gamma$ -lactones by reducing the corresponding ketones diastereoselectively<sup>†</sup> (Scheme 2). Carboxylic acid **6** was converted into acid chloride **7** using thionyl chloride, which was then treated with Grignard reagents to give the ketones **8a** {m.p. 56–58 °C,  $[\alpha]_D^{25} + 21.3$  (c 1.0 MeOH)} and **8b** {m.p. 53–54 °C,  $[\alpha]_D^{25} + 15.7$  (c 1.0 CHCl<sub>3</sub>)}.<sup>‡</sup> The reduction of


these ketones was then studied. Reduction with sodium borohydride afforded a *ca.* 1:2 mixture of *syn*- and *anti*-alcohols, whereas *syn*-alcohols **9a** {m.p. 71–72 °C,  $[\alpha]_D^{20} + 16.0$  (c 1.0 MeOH)} and **9b** {oil,  $[\alpha]_D^{25} + 61.7$  (c 0.7 CHCl<sub>3</sub>); lit.,<sup>4</sup>  $[\alpha]_D^{21} + 59.8$  (c 1.04 CHCl<sub>3</sub>)} were diastereoselectively obtained by reducing with L-Selectride (*syn*:*anti* = >30:1



Scheme 1

<sup>†</sup> All new compounds gave satisfactory spectral data and elemental analyses.

<sup>‡</sup> Although Larchevêque *et al.* reported that the ketones corresponding to **8a** or **8b** were rapidly racemized,<sup>5</sup> our compounds **8a** and **8b** were stable and showed the same optical rotations after standing over four months at room temperature.



**Scheme 2. Reagents and conditions:** i, SOCl<sub>2</sub>, reflux; ii, cyclo-C<sub>6</sub>H<sub>11</sub>CH<sub>2</sub>MgBr or PhCH<sub>2</sub>MgCl, THF, -78 °C; iii, L-Selectride, THF, -78 °C; iv, MsCl, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; v, LiBr, THF, reflux; vi, NaN<sub>3</sub>, DMPU, room temp.; vii, H<sub>2</sub>, Pd/C, (Boc)<sub>2</sub>O, AcOEt, room temp.; viii, LDA, THF, -78 °C, then MeI

and 10 : 1).<sup>5</sup> The configuration of the new asymmetric carbon was confirmed by comparison with reported spectral data.<sup>4</sup>

The next stage was to convert these *syn*-alcohols into the desired *syn*-amino  $\gamma$ -lactones. Mesylation of the *syn*-alcohols **9a** and **9b** with mesyl chloride and triethylamine followed by two S<sub>N</sub>2 processes, substitution with LiBr and azidation with NaN<sub>3</sub>, yielded the azides **13a** and **13b**, respectively. While the yield of **13a** was good, only a modest yield of **13b** was achieved, because a large amount of elimination product (61%) was produced during treatment of **12b** with NaN<sub>3</sub>. Catalytic hydrogenation of the azides **13a** and **13b** over Pd/C in the presence of (Boc)<sub>2</sub>O§ afforded the desired *N*-Boc- $\gamma$ -

lactones **14a** {m.p. 62–64 °C, [ $\alpha$ ]<sub>D</sub><sup>20</sup> -28.6 (c 1.0 MeOH); lit.,<sup>1g</sup> [ $\alpha$ ]<sub>D</sub><sup>23</sup> -28.0 (c 2.48 CHCl<sub>3</sub>)} and **14b** {m.p. 94–95 °C, [ $\alpha$ ]<sub>D</sub><sup>25</sup> +1.2 (c 0.85 CHCl<sub>3</sub>); lit.,<sup>1h</sup> m.p. 95 °C}, respectively.<sup>6</sup> These intermediates were chemically stable and did not show decomposition after storage at room temperature for several months. Further, deprotonation of **14a** by LDA followed by addition of MeI gave the *trans*-methylated  $\gamma$ -lactone predominantly. After purification by silica gel chromatography, pure *trans*- $\gamma$ -lactone **15** {m.p. 80–82 °C, [ $\alpha$ ]<sub>D</sub><sup>20</sup> -24.5 (c 1.0 CHCl<sub>3</sub>)} was easily obtained. Although a small amount of dimethylated  $\gamma$ -lactone (4%) was also obtained, the *cis*-methylated  $\gamma$ -lactone could not be isolated.

In conclusion, we have succeeded in an efficient synthesis of hydroxyethylene dipeptide isostere precursors,  $\gamma$ -lactones, utilizing the chirality of L-glutamic acid. This method will also serve in the preparation of hydroxyethylene dipeptide isosteres with non-proteinogenic side chains by choosing appropriate Grignard and alkylating reagents.

Received, 1st July 1992; Com. 2/03490E

## References

- (a) M. Szelke, D. M. Jones, B. Atrash, A. Hallett and B. J. Leckie, *Proc. Am. Pept. Symp. (8th)*, 1983, 579; (b) M. W. Holladay and D. H. Rich, *Tetrahedron Lett.*, 1983, **24**, 4401; (c) A. H. Fray, R. L. Kaye and E. F. Kleinman, *J. Org. Chem.*, 1986, **51**, 4828; (d) H. Yanagisawa, T. Kanazaki and T. Nishi, *Chem. Lett.*, 1989, 687; (e) T. Nishi, M. Kataoka and Y. Morisawa, *Chem. Lett.*, 1989, 1993; (f) M. Shiozaki, T. Hata and Y. Furukawa, *Tetrahedron Lett.*, 1989, **30**, 3669; (g) H. Kotsuki, A. Miyazaki and M. Ochi, *Tetrahedron Lett.*, 1991, **32**, 4503; (h) A. K. Ghosh, S. P. McKee and W. J. Thompson, *J. Org. Chem.*, 1991, **56**, 6500, and references cited therein.
- W. J. Greenlee, *Med. Res. Rev.*, 1990, **10**, 173; C. Debouk and B. W. Metcalf, *Drug Dev. Res.*, 1990, **21**, 1 and references cited therein.
- C. Eguchi and A. Kakuta, *Bull. Chem. Soc. Jpn.*, 1974, **47**, 1704.
- H. Kotsuki, A. Miyazaki, M. Ochi and J. J. Sims, *Bull. Chem. Soc. Jpn.*, 1991, **64**, 721.
- M. Larchevêque and J. Lalande, *J. Chem. Soc., Chem. Commun.*, 1985, 83.
- S. Saito, H. Nakajima, M. Inaba and T. Moriwake, *Tetrahedron Lett.*, 1989, **30**, 837.

§ Abbreviations: Boc = *tert*-butoxycarbonyl, LDA = lithium diisopropylamide, Ms = methanesulfonyl, DMPU = *N,N'*-dimethylpropyleneurea.